Last reviewed · How we verify
insulin dose increase
At a glance
| Generic name | insulin dose increase |
|---|---|
| Also known as | Long acting insulin (Lantus) |
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants (PHASE1)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Fasted Exercise Training in Type 1 Diabetes (FED-T1D) (NA)
- Empagliflozin Adjunctive Therapy in Bipolar Depression (NA)
- Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose (NA)
- Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus (PHASE3)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin dose increase CI brief — competitive landscape report
- insulin dose increase updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI